What Is a Stapled Peptide?

What stapling does to a peptide

Many protein-protein interactions are mediated by a short helical segment of one partner. A synthetic peptide that copies that segment is usually unstructured in solution, because the isolated helix has no folded protein to stabilise it. Stapling replaces that missing stabilisation with a covalent bridge.

Two non-natural amino acids carrying terminal alkenes are placed on the same face of the helix, and a ruthenium-catalysed ring-closing metathesis joins them into a carbon bridge. The bridge spans a defined number of residues, so the peptide is constrained to a helix of the corresponding length. The result is a molecule with higher helical content, a more ordered binding surface and, often, better resistance to proteases.

Stapling is a constraint strategy, not a labelling strategy. The bridge is not designed to be detected or captured; it is designed to hold a shape. That distinguishes it from the tags and polymers covered in peptide modification.

i, i+4 and i, i+7: choosing the staple positions

An alpha-helix has about 3.6 residues per turn. Two residues separated by four positions (i and i+4) sit roughly one turn apart on the same face. Two residues separated by seven positions (i and i+7) sit about two turns apart, also on the same face. Placing the alkenyl residues at either spacing lets the bridge run along one side of the helix without crossing the binding interface.

The i, i+4 staple is shorter and tighter and is common in peptides of 10–14 residues. The i, i+7 staple spans a longer distance and is used for longer helical segments or when an i, i+4 pair would sit inside the binding epitope. Mixed patterns and double staples exist, but each additional bridge adds synthetic difficulty and reduces the chance of finding a soluble product.

Position choice should follow structural data, not a rule of thumb. A staple on the binding face will block the interaction it was meant to improve.

How a stapled peptide is made

The synthesis is solid-phase peptide synthesis with two alkenyl amino acids inserted at the chosen positions. The most widely used residues are S5 (two carbons beyond the alpha carbon, giving a C8 bridge after metathesis) and R8 (five carbons, giving a C11 bridge). Both are commercially available as Fmoc building blocks.

Ring-closing metathesis is usually performed on resin, before cleavage. The resin-bound peptide is swollen in dichloromethane or dichloroethane, treated with a Grubbs catalyst — commonly a second-generation Grubbs or Hoveyda-Grubbs catalyst — and stirred until the bridge forms. On-resin conditions simplify work-up because the catalyst and small-molecule by-products are washed away, while the peptide stays attached.

Solution-phase metathesis is possible and is chosen when the on-resin reaction is slow or when the resin is incompatible with the solvent. It requires the protected peptide to be soluble, which is not always the case. After metathesis, the peptide is cleaved, the side-chain protecting groups are removed and the product is purified by reverse-phase HPLC.

Ethylene is a by-product of the reaction and is normally removed by sparging or by working under a slight vacuum. Incomplete metathesis leaves the di-alkene precursor, which is close in mass to the product and can be difficult to separate. Successful routes are usually confirmed by LC-MS before scale-up.

Effects on helicity, proteolysis and cell uptake

Helicity. Circular dichroism usually shows a large increase in alpha-helical content after stapling. The bridge reduces the entropic cost of folding, so the peptide spends more time in the bound conformation. That can raise affinity even when the contact residues are unchanged.

Proteolysis. A helix is a poor substrate for many proteases, and the bridge physically blocks access to the backbone. Stapled peptides often survive in plasma for hours where the unstapled parent lasts minutes. The effect is sequence-dependent: a staple that leaves a flexible terminus exposed does not protect that terminus.

Cell uptake. Some stapled peptides enter cells better than their linear parents, but the effect is inconsistent and mechanism is debated. Hydrophobicity, charge and staple length all contribute, and much of the reported uptake may reflect membrane association rather than productive cytosolic delivery. The claim should be tested with a functional readout, not assumed from a structural change.

Common pitfalls: stereochemistry, catalyst removal and solubility

Stereochemistry. The alkenyl building blocks introduce a stereocentre, and the metathesis can produce E and Z isomers. The E isomer is usually the intended product, but a mixture of isomers creates two products with the same mass and different retention times. Building blocks of defined stereochemistry and controlled reaction conditions reduce the problem, but some isomerisation is always possible.

Catalyst removal. Ruthenium residues bind to peptides and can remain after HPLC, showing up as coloured or metal-contaminated product. Extensive washing on resin, a chelating wash, or a scavenger treatment during cleavage helps. Residual metal matters for cell assays and for any product that will be characterised by sensitive analytical methods.

Solubility. Hydrocarbon bridges are greasy. A stapled peptide is often less soluble than the parent, and the increase in helicity can promote aggregation. Choosing the staple position away from hydrophobic stretches, or adding a solubilising residue at a terminus, is often necessary. Peptide solubility covers the practical handling options.

Incomplete reaction. Steric hindrance around the alkenyl residues can slow metathesis, particularly with bulky neighbouring residues. Repeating the catalyst treatment or switching to a more active catalyst usually resolves it, at the cost of yield.

When to use a staple instead of a full ring

A staple and a head-to-tail ring solve different problems. A full ring constrains the whole backbone and is usually chosen for short peptides that must resist proteases or mimic a cyclic natural product. A staple constrains a local helical segment while leaving the termini free to extend or to carry a tag.

If the target epitope is a helix, a staple is usually the better fit because it reinforces the exact conformation that binds. If the goal is general metabolic stability or a rigid scaffold, a cyclic peptide is often simpler and cheaper. If the peptide needs a fluorophore as well, the staple can be placed on the opposite face and the dye attached at a terminus.

Cost and lead time follow from the extra steps: two non-natural residues, a metathesis step, an isomer separation and a more demanding purification. A stapled peptide is a development project, not a catalogue item, and the sequence should be reviewed before a quote is fixed.

What a stapled peptide order should specify

Give the sequence with the two alkenyl residues marked by position, the intended staple pattern (i, i+4 or i, i+7), the required staple length if known, and the target helicity or assay. State whether the C-terminus should be free or amidated and whether a tag is needed.

Ask for the analytical package in advance. A stapled peptide should be released with an HPLC chromatogram, an LC-MS mass that matches the closed bridge, and a note on isomer content if two peaks are observed. Circular dichroism data are useful but are usually a separate study rather than a release test.

MOL Changes produces stapled peptides as part of its stapled peptide service, from 5 mg to larger scale, with HPLC purity confirmed by the same methods described in purity testing.